Nuveen LLC bought a new position in shares of Utah Medical Products, Inc. (NASDAQ:UTMD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 8,018 shares of the medical instruments supplier's stock, valued at approximately $449,000. Nuveen LLC owned approximately 0.24% of Utah Medical Products as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its holdings in Utah Medical Products by 12.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 13,119 shares of the medical instruments supplier's stock worth $735,000 after acquiring an additional 1,421 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Utah Medical Products by 134,400.0% in the 1st quarter. GAMMA Investing LLC now owns 4,035 shares of the medical instruments supplier's stock worth $226,000 after buying an additional 4,032 shares during the last quarter. Millennium Management LLC grew its position in Utah Medical Products by 27.8% during the fourth quarter. Millennium Management LLC now owns 32,087 shares of the medical instruments supplier's stock valued at $1,972,000 after buying an additional 6,975 shares during the period. Northern Trust Corp increased its holdings in Utah Medical Products by 5.1% during the fourth quarter. Northern Trust Corp now owns 36,832 shares of the medical instruments supplier's stock worth $2,264,000 after buying an additional 1,773 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Utah Medical Products by 4.3% in the fourth quarter. Two Sigma Investments LP now owns 19,190 shares of the medical instruments supplier's stock worth $1,180,000 after acquiring an additional 783 shares during the period. 69.60% of the stock is owned by institutional investors.
Utah Medical Products Price Performance
Shares of Utah Medical Products stock traded down $2.02 on Wednesday, reaching $60.78. 8,363 shares of the company traded hands, compared to its average volume of 12,721. The company has a 50 day moving average of $58.28 and a 200 day moving average of $56.40. Utah Medical Products, Inc. has a 52 week low of $51.26 and a 52 week high of $68.99. The firm has a market capitalization of $195.10 million, a PE ratio of 16.25 and a beta of 0.32.
Utah Medical Products (NASDAQ:UTMD - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $0.94 EPS for the quarter. Utah Medical Products had a return on equity of 10.55% and a net margin of 32.34%.The business had revenue of $9.95 million for the quarter.
Utah Medical Products Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 2nd. Stockholders of record on Wednesday, September 17th will be given a dividend of $0.305 per share. This represents a $1.22 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Wednesday, September 17th. Utah Medical Products's dividend payout ratio is currently 32.62%.
About Utah Medical Products
(
Free Report)
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Featured Stories

Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.